Hypolipemiant besides antileukemic effect of imatinib mesylate.
Leuk Res
; 33(9): 1285-7, 2009 Sep.
Article
em En
| MEDLINE
| ID: mdl-19327828
ABSTRACT
The use of imatinib mesylate (IM) (Gleevec, Novartis) in chronic myeloid leukemia (CML) and other neoplastic disorders is in a dramatic increase, inducing long-standing survival. Therefore, the interest in the associated events with this treatment is more and more manifest. We describe a case of CML in which, at the usual antileukemic dose, IM induced a rapid and persistent normalization of the levels of serum cholesterol, triglycerides, low- and high-density lipoproteins and glucose. In the present case report we confirm other observations on the hypolipemiant and antidiabetic effects, concomitant with that antileukemic, of IM.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Hipolipemiantes
/
Antineoplásicos
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article